Valuation: Tonix Pharmaceuticals Holding Corp.

Market Cap 54.8M 49.97M 46.21M 41.7M 78.53M 5.12B 81.63M 558M 221M 2.76B 206M 201M 8.73B P/E 2026 *
-0.26x
P/E 2027 * -0.48x
Enterprise Value 54.8M 49.97M 46.21M 41.7M 78.53M 5.12B 81.63M 558M 221M 2.76B 206M 201M 8.73B EV / Sales 2026 *
0.94x
EV / Sales 2027 * 0.5x
Free-Float
99.11%
Yield 2026 *
-
Yield 2027 * -
11-09 Tonix Pharmaceuticals Holding Corp., Q3 2026 Earnings Call, Nov 09, 2026
11-09 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
11-02 Tonix Pharmaceuticals Holding Corp. Announces Appointment of George Lederman as Executive Vice President, Strategy and Transformation, Effective October 30, 2026 CI
10-27 Tonix Pharmaceuticals Holding Corp. Presents Analysis Of Phase 3 Data Demonstrating TONMYA Improved Physical Symptoms And Functional Ability Of Patients With Fibromyalgia CI
10-26 Canaccord Genuity Initiates Coverage on Tonix Pharmaceuticals With Buy Rating, $18 Price Target MT
09-22 Tonix Pharmaceuticals Holding Corp. Announces Second Major Managed Medicare Payer Agreement for TONMYA® CI
09-08 Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026 CI
08-18 Tonix Pharmaceuticals Holding Corp. Announces Appointment of Seth Lederman as Interim Chief Medical Officer CI
08-10 Tonix Pharmaceuticals Holding Corp., Q2 2026 Earnings Call, Aug 10, 2026
08-10 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-03 Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
07-21 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
07-15 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
1 day-4.08%
1 week-27.13%
Current month-44.71%
1 month-53.31%
3 months-77.73%
6 months-80.22%
Current year-81.95%
1 week 2.77
Extreme 2.77
3.25
1 month 2.77
Extreme 2.77
6.04
Current year 2.77
Extreme 2.77
19.95
1 year 2.77
Extreme 2.77
20.56
3 years 2.77
Extreme 2.77
2,213.76
5 years 2.77
Extreme 2.77
362,880
10 years 2.77
Extreme 2.77
602,564,102.56
Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer - 03/12/2024
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 A Other

Executive/Senior Manager

60,174 0.5110%
8/27/26 A Buy

Chief Executive Officer

2,000 0.0170%
8/20/26 A Buy

Director

1,000 0.0085%
Change 5-day change 1-year change 3-year change Capi.($)
-4.08%-27.13%-82.71%-99.81% 57.13M
-2.32%-3.79%+34.24%+133.69% 1,261B
-2.15%-2.75%+36.35%+82.05% 671B
-2.33%-3.04%+22.29%+106.80% 518B
-0.69%+0.37%+31.53%+69.78% 387B
-3.90%-6.39%+42.88%+35.41% 353B
-1.35%-0.95%+28.90%+56.34% 300B
-1.13%-1.80%+0.59%+33.00% 283B
-3.07%-5.17%+29.04%+67.26% 248B
-0.75%-0.44%+32.87%+123.96% 211B
Average -1.31%-3.92%+17.60%+60.85% 423B
Weighted average by Cap. -0.78%-0.55%+30.58%+91.57%

Financials

2026 *2027 *
Net sales 58.24M 53.12M 49.11M 44.32M 83.47M 5.44B 86.76M 593M 234M 2.94B 219M 214M 9.28B 110M 100M 92.59M 83.56M 157M 10.26B 164M 1.12B 442M 5.54B 412M 403M 17.49B
Net income -186M -170M -157M -142M -267M -17.38B -277M -1.89B -749M -9.38B -698M -683M -29.63B -184M -168M -156M -140M -264M -17.24B -275M -1.88B -743M -9.3B -692M -677M -29.38B
Net Debt - -
Projected Income Statement - Annual - Tonix Pharmaceuticals Holding Corp.
Logo Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
142
Date Price Change Volume
18/11/26 $2.820 -4.08% 1,043,068
17/11/26 $2.940 +2.08% 743,852
16/11/26 $2.880 -4.32% 1,215,451
13/11/26 $3.010 -7.10% 1,935,104
12/11/26 $3.240 -16.28% 2,454,547
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Tonix Pharmaceuticals Holding Corp.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.940USD
Average target price
31.60USD
Spread / Average Target
+974.83%
  1. Stock Market
  2. Stocks
  3. TNXP Stock